戻る Agenda
Session 4 - Regenerative Medicine Clinical Strategy
Session Chair(s)
Kiyoshi Okada, MD, PHD
Professor , Deputy Director, Regenerative Medicine Support Office, Future Medica
the University of Osaka & the University of Osaka Hospital, Japan
Keiji Miyamoto
Principal Post-Marketing Regulatory Affairs Dep.
Daiichi Sankyo Co.,Ltd., Japan
Speaker(s)
Conditional Approval for HeartSheet (R)
Tadashi Sameshima
Terumo Corporation, Japan
Executive Officer/GM HeartSheetBusiness Dept, Project Leader, R&D
Challenges and Considerations Regarding Control Group in Surgical Delivery of Cell Therapy
James Baldassarre, MD
Janssen Research & Development, LLC, A Pharmaceutical Company of Johnson & Johns, United States
Head of Clinical Development, Cell Therapy
Our Current Business Status and Issues in Japanese Market of Regenerative Medicinal Products
Ken-Ichiro Hata, MD, PHD
Japan Tissue Engineering Co., Ltd., Japan
Senior Advisor
Development of MultiStem (R) - An Allogeneic Stem Cell Therapy for the Treatment of Ischemic Stroke
Gil Van Bokkelen, PHD
Athersys, Inc., United States
Chairman & Chief Executive Officer